Related to Biotie Restructures to Focus on Clinical Pipeline Headed by Lundbeck-Partnered Nalmefene

• Merck & Co. and Roche Go Global with Marketing for Victrelis in HCV
  
• PerkinElmer to Take Over Distribution of NimbleGen CGX Cytogenetics Array Workflow from Roche
  
• Roche Pays Evotec $10M Up Front in Deal to Develop MAO-B Inhibitor for Alzheimer Disease
  
• Roche Establishes Links with Swedish Academic Innovation Initiative
  
• Lundbeck Makes £10.3M Investment in Proximagen to Bolster R&D in CNS Diseases
  
• Roche Acquires License to Nanopore Technology with Sights on $1,000 Whole Genome Sequencing
  
• Roche Gives Arrowhead RNAi Assets and Facility in Madison, WI
  
• Roche and Aileron Pin Third Program to Stapled Peptide Drug Collaboration
  
• Roche Nabs PTC’s SMA Program for $30M Up Front
  
• Roche, Swiss Academia Establish Translational Research Collaboration
  
• Roche, Technoclone Partner to Develop Coagulation Assays
  
• EC Clears Roche, Plexxikon’s Zelboraf for BRAF V600-Mutated Melanoma
  
• Academia-Industry Project Secures $38.7M for Autism Spectrum Disorders
  
• Roche Plans 2012 Filing for Breast Cancer Antibody-Drug Conjugate
  
• Biotie Regains Asia-Pacific Rights for VAP-1 Antibody Program from Seikagaku
  
• ThromboGenics, BioInvent Regain TB-403 from Roche and Ditch Anticoagulant TB-402
  
• Roche Goes to Seaside for Collaboration on Fragile X Syndrome, Autism Therapies
  
• Galapagos and Roche Call It Quits
  
• Roche, Ascletis to Develop HCV Drug in China
  
• Lundbeck and Biotie Report Alcohol Dependence Therapy Success in Two Phase III Studies